JPRN-UMIN000007203
Completed
未知
A clinical study of combination drug against type 2 diabetes - Glubes combination tablets for patients poorly controlled with a-GI or Glinide - - A clinical study of combination drug against type 2 diabetes - Glubes combination tablets for patients poorly controlled with a-GI or Glinide
Advanced Clinical Research Organization0 sites30 target enrollmentFebruary 3, 2012
Conditionstype2 diabetes
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- type2 diabetes
- Sponsor
- Advanced Clinical Research Organization
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients who are applicable to the \[taboo issue] in a package insert of Glubes combination tablets. Patients who have severe ketosis, precoma or diabetic coma or type 1 diabetes. Patients with severe infection or severe injury. Patients accepting surgery. Patients with a history of hypersensitivity to any component of this drug. Pregnant women and women suspected to be pregnant. 2\) Patients whom the principal investigator and investigators decided not to be appropriate for taking Glubes combination tablets, on the point of \[Special caution needed] and \[side effects] in the package insert.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 3
Clinical investigation for combination therapy of KAD-1229 and Pioglitazone.Type 2 diabetesJPRN-jRCT2080220136KISSEI PHARMACEUTICAL CO.,LTD.
Completed
Not Applicable
A clinical study of a combination drug for type2 diabetes -Using self-monitoring of blood glucose and meal tolerance testtype2 diabetesJPRN-UMIN000007202Advanced Clinical Research Organization10
Not yet recruiting
Phase 2
The therapeutic effect of the combination of altplas and ibtifibatide (integrilin) in comparison with altplas (r-TPA) alone, in the treatment of acute ischemic strokeAcute Ischemic Stroke.Cerebellar stroke syndromeG46.4IRCT20170117032025N9Hamedan University of Medical Sciences50
Completed
Phase 2
Phase II clinical study of the combination chemotherapy regimen of topotecan plus oral etoposide for the treatment of recurrent ovarian cancerResistant ovarian cancerJPRN-UMIN000007318Kyorin University, School of Medicine20
Not yet recruiting
Phase 3
Effect of medicated enema and ayurvedic medicine on PCOSHealth Condition 1: E282- Polycystic ovarian syndromeCTRI/2021/02/031599Ch Brahm Prakash Ayurved Charak Sansthan